Related Experiment Video
Updated: Jul 3, 2026

Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds
Published on: September 8, 2021
Lysostaphin: an antistaphylococcal agent.
1Department of Biochemistry, National University of Singapore, Kent Ridge, Singapore. bchjkk@nus.edu.sg
Lysostaphin, an enzyme targeting Staphylococcus aureus, shows promise for treating antibiotic-resistant infections. Its unique action on bacterial cell walls offers a new therapeutic avenue against MRSA.
Area of Science:
- Biochemistry
- Microbiology
- Enzymology
Background:
- Staphylococcus aureus infections pose a significant global health threat, exacerbated by rising antibiotic resistance.
- Methicillin-resistant Staphylococcus aureus (MRSA) is a particularly challenging pathogen requiring novel therapeutic strategies.
- Lysostaphin is a metalloenzyme with specific lytic activity against Staphylococcus aureus.
Purpose of the Study:
- To review the current understanding of lysostaphin's enzymatic activities and its mechanism of action.
- To explore the therapeutic potential of lysostaphin as a treatment for antibiotic-resistant Staphylococcus aureus and MRSA infections.
- To discuss the application of lysostaphin as a standalone or combination therapy.
Main Methods:
- Literature review of existing studies on lysostaphin.
- Analysis of lysostaphin's enzymatic properties, including glycylglycine endopeptidase, endo-beta-N-acetyl glucosamidase, and N-acteyl muramyl-L-alanine amidase activities.
- Evaluation of lysostaphin's efficacy against Staphylococcus aureus and MRSA in various experimental models.
Main Results:
- Lysostaphin specifically cleaves glycine-glycine bonds in the Staphylococcus aureus cell wall interpeptide cross-bridge.
- The enzyme exhibits potent lytic activity against Staphylococcus aureus, including resistant strains.
- Lysostaphin demonstrates potential for treating MRSA infections, both alone and in combination with existing antibiotics.
Conclusions:
- Lysostaphin's unique specificity and lytic action make it a promising therapeutic agent against Staphylococcus aureus.
- Further research and clinical trials are warranted to fully establish lysostaphin's role in combating antibiotic-resistant staphylococcal infections.
- Lysostaphin represents a valuable addition to the arsenal against challenging MRSA infections.
More Related Videos
11:59Isolation of Lipoprotein Particles from Chicken Egg Yolk for the Study of Bacterial Pathogen Fatty Acid Incorporation into Membrane Phospholipids
Published on: May 15, 2019
11:56Antimicrobial Peptides Produced by Selective Pressure Incorporation of Non-canonical Amino Acids
Published on: May 4, 2018
Related Concept Videos
Staphylococcal Skin Infections
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Gram-positive Cell Wall Synthesis
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Antifungal Agents
Clinical Significance of Antibiotic Resistance